title: [USAGE OF PRONORAN® FOR TREATMENT OF ELDERLY PATIENTS WITH MILD COGNITIVE IMPAIRMENT].
abstract: Evaluated the effectiveness of Pronoran® for treatment of elderly patients with syndrome of mild cognitive impairment (MCI) with underlying dyscirculatory encephalopathy. The study involved 48 people: I (main) group--27 patients who in addition to basic therapy received Pronoran®, II (control) group--21 patients, received only basic therapy. We found that exposure to a 3-month treatment course for patients of the I (main) group showed significant improvement in terms of indicators characterizing orientation in space, short-term memory, counting ability, concentration, psychomotor pace, ability to learn. In addition, the treatment course was accompanied by improved emotional state, positive changes in the coefficients of the spectral power qEEG for patients. At the same time, the patients in the II (control) group didn't show significant changes in the studied parameters.
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Bachyns'ka
authors.forename: I F
authors.initials: IF
authors.lastname: Rozheliuk
mesh_terms: D000368:Aged; D000375:Aging / Q000523:psychology*; D001927:Brain Diseases / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D003072:Cognition Disorders / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004569:Electroencephalography; D006801:Humans; D010891:Piribedil / Q000008:administration & dosage / Q000627:therapeutic use*; D017448:Receptors, Dopamine D2 / Q000819:agonists; D050637:Receptors, Dopamine D3 / Q000819:agonists; D012720:Severity of Illness Index
chemical_list: C581293:DRD2 protein, human; D018491:Dopamine Agonists; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D010891:Piribedil